Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilitiesCarl M. Gay, Lauren A. Byers, Qi Wang et al.|Cancer Cell|2021Cited by 930
Adenovirus-Mediated p53 Gene Transfer in Advanced Non-Small-Cell Lung CancerStephen G. Swisher, Martin Waugh, Jack A. Roth et al.|JNCI Journal of the National Cancer Institute|1999Cited by 497
Improved graft patency in patients treated with platelet-inhibiting therapy after coronary bypass surgery.B. Greg Brown, Joseph S. Carey, Ramon A. Cukingnan et al.|Circulation|1985Cited by 168
EGFR-targeted plasmonic magnetic nanoparticles suppress lung tumor growth by abrogating G2/M cell-cycle arrest and inducing DNA damageRajagopal Ramesh, Jack A. Roth|International Journal of Nanomedicine|2014Cited by 41
Exogenous Restoration of TUSC2 Expression Induces Responsiveness to Erlotinib in Wildtype Epidermal Growth Factor Receptor (EGFR) Lung Cancer Cells through Context Specific Pathways Resulting in Enhanced Therapeutic EfficacyBingbing Dai, Jack A. Roth|PLoS ONE|2015Cited by 30